Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
With about millions of people who live Parkinson’s disease In the US – and 90,000, they receive new diagnoses every year – the race continues for treatment.
Researchers of the Sloan Kettering Memorial Center (MSK) have announced progress on this front – they have developed a new therapy that uses stem cells to treat advanced Parkinson.
During the phase 1 test, the researchers used donated stem cells (Embrony Embrony) to create nerve cells (neurons) and transplanted them into the brain of 12 Parkinson, MSK said.
New Parkinson’s new drug that has shown itself effective in clinical trials: “Very encouraged”
Once the cells are administered, they produce dopamine, the hormone in the brain that helps with movement and coordination.
(One of the distinctive features of Parkinson is the low level of dopamine, which causes typical jolt symptoms, stiffness, balance problems and walking difficulty.)
About one million people live with Parkinson’s illness in the US, and 90,000 get new diagnoses each year. (Istock)
After 18 months, the injection cells “became interested in the brain without serious side effects,” the researchers said.
Based on MDS-UPDRS-Shkal ratings for symptoms developed by the International Parkinson Society and the Movement Member has experienced “noticeable improvements”, especially the group that received a A higher dose.
Patients in a high dose group reported 2.7 hours of additional “timely”.
“Neurologists say that with this disease everything usually becomes a little worse, it means that the number is increasing by several points,” Lorenz Studer, MDK MSK, said in a press release.
“Not only did the score not deteriorate in our study, but in a high dose group it fell by more than 20 points.”
Researchers used donated stem cells (early -stage embryos) to create nerve cells (neurons) and transplant them into the brains of 12 Parkinson patients. (Istock)
On average, patients in a high dose group reported 2.7 hours of additional “timely”-indicating periods of normal functioning with minimal symptoms- “result that can be very significant for their daily life,” the student said.
Given the success of the trial of Phase 1, the US Power Office and the US Medicines (FDA) provided permission to researchers at once before A, Phase 3 clinical trial In a much larger group of patients – about 100 people – which will take place in the first half of 2025.
The results were published in Nature.
Parkinson’s cases may double the world by 2050, shows the study
“The study found that the development of specific nerve cells from the human embryonic stem cells into the laboratory, and then their introduction to the brain of people with Parkinson’s disease is safe and has a significant perspective like A possible treatment“The author of the leading study Vivian Tabor, MD, the chairman of the department of neurosurgery at the Ketering Cancer Memorial Cancer in New York, said Fox News Digital.
“The conclusions were useful because this work was more than a decade.”
“Main step forward”
Dr. Mary Anne Picon, Medical Director of the CU Center in the Medical Center of the Holy Name in Theoneci, New Jersey, said cells for the treatment of Parkinson’s disease may offer not only a delay in disability, but also to stop the progression and improving improvement of motor function.
“Although the immunity is the risk required before Implantation of stem cells And the procedure itself, this would be the main step forward in replacing the dopaminer’s neurons lost in illness, “said Picone, who did not participate in the study, said Fox News Digital.
Click here to get the Fox News app
Levodopa, now the first-line treatment for Parkinson, is limited by the fact that patients need a larger number of dosage over time, according to Piko- “regulation, during the stiffness or dyskinesia (uncontrolled muscle movements) becomes more complicated.”
After 18 months, the injection cells “became interested in the brain without serious side effects,” the researchers said. (Istock)
Dr. Anne Murray, Director of Movement Violations at the WVU Rockefeller Institute in Western Virginia Names The study “incredibly exciting“For Parkinson patients.
“Although the purpose of this particular scientific and research project was to ensure security, obtaining a significant clinical improvement updars is absolutely innovative,” said Murray Fox News Digital. (She also did not participate in the study.)
Click here to subscribe to our health newsletter
“This is just the first step in obtaining this type of therapy approved by patients suffering from Parkinson’s disease, but this is an amazing first step for potential benefits Stem cell brain therapy“
Potential restrictions
The camp noted some restrictions related to the study.
“This is a small study intended to show security-very importantly conduct a wide, well-controlled study to prove that treatment really works, otherwise called the” phase 3 “efficiency study,” she said.
“This is an amazing first step for potential stem cell brain.”
However, these early conclusions “testify to the great promise.”
“I think we can finally say that stem cells, with the right and differentiated other conditions If -no, ”the camp said.
For additional health articles visit www.foxnews.com/health
Cell therapy was developed in MSK and received a license on Bluerock Therapeutics in Massachusetts, which financed the study.
